Immunogenicity of drug delivery vehicles remains unpredictable and limits therapeutic efficacy in advanced treatments

Researchers and pharmaceutical developers struggle with immune system rejection of drug delivery vehicles like liposomes, which undermines the effectiveness of cutting-edge treatments for serious diseases like HIV. Current solutions are incomplete and inconsistent, forcing scientists to spend months or years troubleshooting immunogenicity issues that delay clinical progress and increase development costs. The lack of practical, generalizable solutions means each new drug delivery system requires extensive custom immunogenicity testing and redesign.